Filed pursuant to Rule 424(b)(5)
Registration No. 333-275935
PROSPECTUS SUPPLEMENT
(to Prospectus dated January 2, 2024)
Up to $9,145,000 of Common Stock
This prospectus supplement amends and supplements
the information in the prospectus, dated January 2, 2024, filed as part of our registration statement on Form S-3, as amended (File No.
333-275935), or the Registration Statement, as supplemented by our prospectus supplements dated January 2, 2024, February 24, 2025, August
13, 2025 and June 16, 2026, or collectively, the Prior Prospectuses, relating to the offering, issuance and sale by us of our shares of
common stock, par value $0.0001 per share, or the Common Stock, from time to time that may be issued and sold under the At The Market
Offering Agreement, dated December 7, 2023, or the Sales Agreement, by and between us and H.C. Wainwright & Co., LLC, or Wainwright,
as sales agent. Through the date hereof, we have sold an aggregate of $3,708,127 of shares of our Common Stock through the sales agent
under the Sales Agreement and the Prior Prospectuses.
This prospectus supplement should be read in conjunction
with the Prior Prospectuses, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes
the information contained in the Prior Prospectuses. This prospectus supplement is not complete without, and may only be delivered or
utilized in connection with, the Prior Prospectuses, and any future amendments or supplements thereto.
We are filing this prospectus supplement to amend
the Prior Prospectuses to update the maximum aggregate offering price of shares of our Common Stock that may be offered and sold under
the Registration Statement pursuant to General Instruction I.B.6 of Form S-3. As a result of these limitations and the current public
float of our shares of Common Stock and in accordance with the terms of the Sales Agreement, we may offer and sell shares of Common Stock
having an aggregate offering price of up to $9,145,000 from time to time through Wainwright, which does not include the shares of Common
Stock having an aggregate sales price of approximately $3,708,127 that were sold pursuant to the Prior Prospectuses to date. In the event
that we may sell additional amounts under the Sales Agreement and in accordance with General Instruction I.B.6, we will file another prospectus
supplement prior to making such additional sales.
The aggregate market value of our shares of Common
Stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $38,560,317.12, which was calculated based on 24,718,152
shares of Common Stock outstanding held by non-affiliates and at a price of $1.56 per share of Common Stock, the closing price of our
shares of Common Stock on May 28, 2026, a date that is within 60 days of filing this prospectus supplement. We have sold an aggregate
of approximately $3,708,127 of securities pursuant to General Instruction I.B.6 of Form S-3 during the 12-calendar month period that ends
on, and includes, the date of this prospectus supplement. As a result of the limitations of General Instruction I.B.6 of Form S-3, and
in accordance with the terms of the Sales Agreement, we currently have the capacity to sell shares of our Common Stock under the Sales
Agreement having an aggregate offering price of up to $9,145,000 from time to time through Wainwright.
Our Common Stock is listed on NYSE American under
the symbol “PHGE.” On July 27, 2026, the last reported sale price for our Common Stock on NYSE American was $0.1948 per share.
The validity of the shares being offered hereby
will be passed upon by Aboudi Legal Group PLLC, New York, New York. This supersedes the information set forth under the heading “Legal
Matters” in the accompanying base prospectus and prospectus supplement dated January 2, 2024.
Investing in our securities involves significant
risks. See “Risk Factors” beginning on page 7 of the prospectus supplement dated January 2, 2024, under the heading “Risk
Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as amended, in our Quarterly Report on Form 10-Q
for the quarter ended March 31, 2026, each of which is incorporated by reference into the Prior Prospectuses, together with the risk factors
and other information contained in the Current Reports on Form 8-K, including our Current Report on Form 8-K dated May 5, 2026, and other
documents that we have filed, or that we file after the date hereof, with the Securities and Exchange Commission and that are incorporated
by reference into this prospectus supplement and the Prior Prospectus, for a discussion of the factors you should carefully consider before
deciding to purchase our Common Stock.
Neither the Securities and Exchange Commission
nor any state or other securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of
this prospectus supplement or the Prior Prospectuses. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
The date of this prospectus supplement is July 27, 2026.
